Anti-angiogenic effects of biotechnological therapies in rheumatic diseases

Francesco Paolo Cantatore,1 Nicola Maruotti,1 Addolorata Corrado,1 Domenico Ribatti2,3 1Rheumatology Clinic, Department of Medical and Surgical Sciences, University of Foggia Medical School, Foggia, 2Department of Basic Medical Sciences, Neurosciences and Sensory Organs, University of Bari Medical S...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Cantatore FP, Maruotti N, Corrado A, Ribatti D
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	angiogenesis biotechnological therapy rheumatic disease Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/befd641cc2d2455daf343cfa3022d61f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:befd641cc2d2455daf343cfa3022d61f
record_format	dspace
spelling	oai:doaj.org-article:befd641cc2d2455daf343cfa3022d61f2021-12-02T11:56:18ZAnti-angiogenic effects of biotechnological therapies in rheumatic diseases1177-5491https://doaj.org/article/befd641cc2d2455daf343cfa3022d61f2017-12-01T00:00:00Zhttps://www.dovepress.com/anti-angiogenic-effects-of-biotechnological-therapies-in-rheumatic-dis-peer-reviewed-article-BTThttps://doaj.org/toc/1177-5491Francesco Paolo Cantatore,1 Nicola Maruotti,1 Addolorata Corrado,1 Domenico Ribatti2,3 1Rheumatology Clinic, Department of Medical and Surgical Sciences, University of Foggia Medical School, Foggia, 2Department of Basic Medical Sciences, Neurosciences and Sensory Organs, University of Bari Medical School, 3National Cancer Institute “Giovanni Paolo II”, Bari, Italy Introduction: Angiogenesis plays a key role in the pathogenesis of numerous rheumatic diseases, such as rheumatoid arthritis, psoriatic arthritis, and vasculitides. Therefore, the inhibition of pathological angiogenesis may be considered a useful therapeutical approach in these rheumatic diseases. Methods: This review article is based on a literature research about the role of biotechnological therapies in angiogenesis inhibition. Results and conclusions: Several evidences have demonstrated a role for biotechnological therapies in angiogenesis inhibition. Nevertheless, further research and clinical trials are needed to better quantify the real impact of biotechnological therapies on pathological angiogenesis. Keywords: abatacept, anakinra, angiogenesis, rituximab, TNF-α, tocilizumabCantatore FPMaruotti NCorrado ARibatti DDove Medical Pressarticleangiogenesisbiotechnological therapyrheumatic diseaseMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol Volume 11, Pp 123-128 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	angiogenesis biotechnological therapy rheumatic disease Medicine (General) R5-920
spellingShingle	angiogenesis biotechnological therapy rheumatic disease Medicine (General) R5-920 Cantatore FP Maruotti N Corrado A Ribatti D Anti-angiogenic effects of biotechnological therapies in rheumatic diseases
description	Francesco Paolo Cantatore,1 Nicola Maruotti,1 Addolorata Corrado,1 Domenico Ribatti2,3 1Rheumatology Clinic, Department of Medical and Surgical Sciences, University of Foggia Medical School, Foggia, 2Department of Basic Medical Sciences, Neurosciences and Sensory Organs, University of Bari Medical School, 3National Cancer Institute “Giovanni Paolo II”, Bari, Italy Introduction: Angiogenesis plays a key role in the pathogenesis of numerous rheumatic diseases, such as rheumatoid arthritis, psoriatic arthritis, and vasculitides. Therefore, the inhibition of pathological angiogenesis may be considered a useful therapeutical approach in these rheumatic diseases. Methods: This review article is based on a literature research about the role of biotechnological therapies in angiogenesis inhibition. Results and conclusions: Several evidences have demonstrated a role for biotechnological therapies in angiogenesis inhibition. Nevertheless, further research and clinical trials are needed to better quantify the real impact of biotechnological therapies on pathological angiogenesis. Keywords: abatacept, anakinra, angiogenesis, rituximab, TNF-α, tocilizumab
format	article
author	Cantatore FP Maruotti N Corrado A Ribatti D
author_facet	Cantatore FP Maruotti N Corrado A Ribatti D
author_sort	Cantatore FP
title	Anti-angiogenic effects of biotechnological therapies in rheumatic diseases
title_short	Anti-angiogenic effects of biotechnological therapies in rheumatic diseases
title_full	Anti-angiogenic effects of biotechnological therapies in rheumatic diseases
title_fullStr	Anti-angiogenic effects of biotechnological therapies in rheumatic diseases
title_full_unstemmed	Anti-angiogenic effects of biotechnological therapies in rheumatic diseases
title_sort	anti-angiogenic effects of biotechnological therapies in rheumatic diseases
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/befd641cc2d2455daf343cfa3022d61f
work_keys_str_mv	AT cantatorefp antiangiogeniceffectsofbiotechnologicaltherapiesinrheumaticdiseases AT maruottin antiangiogeniceffectsofbiotechnologicaltherapiesinrheumaticdiseases AT corradoa antiangiogeniceffectsofbiotechnologicaltherapiesinrheumaticdiseases AT ribattid antiangiogeniceffectsofbiotechnologicaltherapiesinrheumaticdiseases
_version_	1718394832176545792

Anti-angiogenic effects of biotechnological therapies in rheumatic diseases

Ejemplares similares